Adage Capital Partners Gp, L.L.C. Bluebird Bio, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$5.77 - $8.49 $3.61 Million - $5.31 Million	626,000 New	626,000 $4.33 Million
Q3 2020 Nov 16, 2020	SELL	$34.44 - $43.75 $12.9 Million - $16.4 Million	-374,870 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$27.12 - $45.97 $25.2 Million - $42.8 Million	-930,730 Reduced 71.29%	374,870 $22.9 Million
Q1 2020 May 15, 2020	BUY	$26.16 - $63.5 $26.7 Million - $64.8 Million	1,020,600 Added 358.11%	1,305,600 $60 Million
Q4 2019 Feb 14, 2020	BUY	$46.96 - $61.67 $13.4 Million - $17.6 Million	285,000 New	285,000 $25 Million
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $8.65 Million - $11.4 Million	-97,300 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$99.64 - $127.59 $9.69 Million - $12.4 Million	97,300 New	97,300 $15.3 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.